Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26652153 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL10310995 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL12253802 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL10001262 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL14622977 | 0.87 | — | — | |
| SCHEMBL14624334 | 0.85 | — | — | |
| SCHEMBL18098021 | 0.85 | — | — | |
| SCHEMBL21123603 | 0.85 | — | — | |
| SCHEMBL22317546 | 0.85 | — | — | |
| SCHEMBL14537126 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136787-A1 | COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-11180757-B1 | 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136787-A1 | COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION | KDR, VEGFA, FLT4 | FGF1 1716/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | FGF1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.